Utah Revenue Per Share from 2010 to 2024

UTMD Stock  USD 62.74  0.17  0.27%   
Utah Medical's Revenue Per Share is increasing over the years with slightly volatile fluctuation. Overall, Revenue Per Share is expected to go to 14.50 this year. Revenue Per Share is the amount of revenue generated by Utah Medical Products per share of stock, calculated by dividing total revenue by the average number of shares outstanding. View All Fundamentals
 
Revenue Per Share  
First Reported
2010-12-31
Previous Quarter
13.80971497
Current Value
14.5
Quarterly Volatility
3.22540191
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Utah Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Utah Medical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.7 M, Interest Expense of 669.3 K or Total Revenue of 36.6 M, as well as many indicators such as Price To Sales Ratio of 3.45, Dividend Yield of 0.0243 or PTB Ratio of 4.36. Utah financial statements analysis is a perfect complement when working with Utah Medical Valuation or Volatility modules.
  
Check out the analysis of Utah Medical Correlation against competitors.

Latest Utah Medical's Revenue Per Share Growth Pattern

Below is the plot of the Revenue Per Share of Utah Medical Products over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. Utah Medical's Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Utah Medical's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 12.39210 Years Trend
Slightly volatile
   Revenue Per Share   
       Timeline  

Utah Revenue Per Share Regression Statistics

Arithmetic Mean11.19
Geometric Mean9.87
Coefficient Of Variation28.83
Mean Deviation1.76
Median11.20
Standard Deviation3.23
Sample Variance10.40
Range13.74
R-Value0.74
Mean Square Error5.04
R-Squared0.55
Significance0
Slope0.53
Total Sum of Squares145.65

Utah Revenue Per Share History

2024 14.5
2023 13.81
2022 14.37
2021 13.45
2020 11.53
2019 12.61
2018 11.26

About Utah Medical Financial Statements

Utah Medical stakeholders use historical fundamental indicators, such as Utah Medical's Revenue Per Share, to determine how well the company is positioned to perform in the future. Although Utah Medical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Utah Medical's assets and liabilities are reflected in the revenues and expenses on Utah Medical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Utah Medical Products. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Revenue Per Share 13.81  14.50 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Utah Medical Products is a strong investment it is important to analyze Utah Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Utah Medical's future performance. For an informed investment choice regarding Utah Stock, refer to the following important reports:
Check out the analysis of Utah Medical Correlation against competitors.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Utah Medical. If investors know Utah will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Utah Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.05)
Dividend Share
1.2
Earnings Share
4.28
Revenue Per Share
12.392
Quarterly Revenue Growth
(0.20)
The market value of Utah Medical Products is measured differently than its book value, which is the value of Utah that is recorded on the company's balance sheet. Investors also form their own opinion of Utah Medical's value that differs from its market value or its book value, called intrinsic value, which is Utah Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Utah Medical's market value can be influenced by many factors that don't directly affect Utah Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Utah Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Utah Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Utah Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.